Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of T3 on Immune Function in Graves' Disease
ChiCTR-IPR-17010459Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of liothyronine in Graves' disease (4 arms), sponsored by Nanjing First Hospital. Primary endpoint: Thyroid function. Started Jan 2017; status: recruiting.
02
Drugs
liothyronine
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ChiCTR-IPR-17010459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010459.